This is therefore a contrasting of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in TG Therapeutics Inc. (NASDAQ:TGTX) and CEL-SCI Corporation (NYSEAMERICAN:CVM). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics Inc.	N/A	4562.37	173.48M	-2.08	0.00
CEL-SCI Corporation	N/A	323.17	24.42M	-1.24	0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of TG Therapeutics Inc. and CEL-SCI Corporation.

Profitability

Table 2 represents TG Therapeutics Inc. (NASDAQ:TGTX) and CEL-SCI Corporation (NYSEAMERICAN:CVM)’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics Inc.	0.00%	-185%	-127.1%
CEL-SCI Corporation	0.00%	0%	-97.4%

Risk & Volatility

A 2.14 beta indicates that TG Therapeutics Inc. is 114.00% more volatile compared to S&P 500. Competitively, CEL-SCI Corporation is 37.00% more volatile than S&P 500, because of the 1.37 beta.

Liquidity

TG Therapeutics Inc.’s Current Ratio is 2.7 while its Quick Ratio is 2.7. On the competitive side is, CEL-SCI Corporation which has a 1.3 Current Ratio and a 1.2 Quick Ratio. TG Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to CEL-SCI Corporation.

Analyst Recommendations

Ratings and Recommendations for TG Therapeutics Inc. and CEL-SCI Corporation can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
TG Therapeutics Inc.	0	0	2	3.00
CEL-SCI Corporation	0	0	0	0.00

$17.5 is TG Therapeutics Inc.’s consensus target price while its potential upside is 106.61%.

Institutional & Insider Ownership

Roughly 66.1% of TG Therapeutics Inc. shares are held by institutional investors while 8.8% of CEL-SCI Corporation are owned by institutional investors. Insiders held 0.5% of TG Therapeutics Inc. shares. Comparatively, CEL-SCI Corporation has 5.1% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
TG Therapeutics Inc.	37.7%	66.59%	34.45%	-45.58%	-52.57%	66.59%
CEL-SCI Corporation	-7.07%	-9.93%	-19.82%	3.14%	44.51%	-8.36%

For the past year TG Therapeutics Inc. had bullish trend while CEL-SCI Corporation had bearish trend.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companyÂ’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.